Generic Name: Colestipol Hydrochloride
Class: Bile Acid Sequestrants
VA Class: CV350
CAS Number: 37296-80-3
Medically reviewed on November 20, 2017
Antilipemic agent; bile acid sequestrant.
Uses for Colestid
Adjunct to dietary therapy to decrease elevated serum total and LDL-cholesterol concentrations in the management of primary hypercholesterolemia in patients who do not respond adequately to diet.166 167
Generally has no clinically relevant effect on serum triglyceride concentrations,100 167 but may increase triglyceride concentrations in some patients.167 (See Hypertriglyceridemia under Cautions.) Do not use in patients with primary dysbetalipoproteinemia (Fredrickson type III).350
ACC/AHA cholesterol management guideline states that nonstatin drugs (e.g., bile acid sequestrants) do not provide acceptable atherosclerotic cardiovascular disease (ASCVD) risk reduction benefits compared to their potential for adverse effects in the routine prevention of ASCVD.350 May be useful as adjuncts to statin therapy in high-risk patients (e.g., patients with ASCVD, LDL-cholesterol concentrations ≥190 mg/dL, or diabetes mellitus) who have a less-than-anticipated response to statins, are unable to tolerate even a less-than-recommended intensity of a statin, or are completely intolerant to statin therapy.350 Select nonstatin drug based on favorable benefit-risk ratio (i.e., demonstrated benefit of ASCVD risk reduction outweighs risks of adverse effects and drug interactions) and patient preferences.350
Colestid Dosage and Administration
Instruct patients to take other drugs at least 1 hour before or 4 hours after taking colestipol tablets or suspension to minimize possible interference with absorption.166 167 (See Effects on GI Absorption of Drugs under Interactions.)
Monitoring during Antilipemic Therapy
Determine serum cholesterol and triglyceride concentrations prior to and regularly (e.g., every 3–6 months) during colestipol therapy. ACC/AHA cholesterol management guideline recommends obtaining a fasting lipoprotein profile before initiating bile acid sequestrant therapy, after 3 months of therapy, and every 6–12 months thereafter.350
To avoid accidental inhalation or esophageal distress, do not administer colestipol hydrochloride for oral suspension in its dry form.166
To minimize excessive swallowing of air, advise patients to avoid rapid ingestion of suspensions of the drug.136 After the mixture is ingested, rinse the glass with a small amount of additional fluid and ingest the remaining liquid to ensure that the entire dose has been taken.166
Add the prescribed amount of colestipol hydrochloride granules to at least 90 mL of a liquid (e.g., fruit juice, water, milk, soft drink) and stir until completely mixed (colestipol will not dissolve in the liquid).166 Palatability and compliance may be increased if the entire next-day’s dose is mixed in one of these liquids in the evening and then refrigerated.121 Use of a heavy or pulpy fruit juice may minimize complaints about consistency of suspensions of the drug.135 136 166 If a carbonated beverage is used, mix the powder slowly in a large glass to minimize excessive foaming; however, use of a carbonated beverage as a vehicle may be associated with adverse GI effects.166
Alternatively, mix colestipol powder with milk in hot or regular breakfast cereals, a highly fluid soup, or pulpy fruit (e.g., crushed pineapple, pears, peaches, fruit cocktail).166
One dose (1 packet or 1 level teaspoon) of colestipol hydrochloride granules contains 5 g of colestipol hydrochloride.166 One dose (1 packet or 1 level scoop) of flavored colestipol hydrochloride granules contains 7.5 g of granules, which contains 5 g of colestipol hydrochloride.166
Pediatric dosage has not been established;100 166 167 however, dosages of 10–20 g or 500 mg/kg daily in 2–4 divided doses have been used.115 116 118 119 Lower dosages (e.g., 125–250 mg/kg daily) have also been used in some children when serum cholesterol concentrations were only 15–20% above normal after dietary management alone.117
If the desired therapeutic effect is not achieved with the usual dosage of 2–16 g daily with good compliance and acceptable adverse effects, consider combined therapy or alternative treatment.167
If triglyceride concentrations increase markedly, consider reducing dosage, discontinuing therapy, or using combined or alternative treatment.167
Oral (Granules for oral suspension)
Initially, 5 g (1 packet or 1 level scoop) once or twice daily.100 166 Titrate dose upward as necessary in 5-g increments at 1- or 2-month intervals.135 136 166 Usual daily dosage range is 5–30 g (1–6 packets or level scoops) taken once or in divided doses.100 166
If the desired therapeutic effect is not achieved with the usual dosage of 1–6 doses per day with good compliance and acceptable adverse effects, consider combined therapy or alternative treatment.166
If triglyceride concentrations increase markedly, consider reducing dosage, discontinuing therapy, or using combined or alternative treatment.166
Patients with preexisting constipation receiving granules for oral suspension: Initially, 5 g once daily for 5–7 days; then increase dosage to 5 g twice daily and monitor constipation and serum lipoprotein values, at least twice, 4–6 weeks apart.166 Thereafter, increase dosage as needed by 1 dose per day (at monthly intervals) with periodic monitoring of serum lipoprotein values;166 adjust dosage accordingly to achieve the desired effect while avoiding excessive dosage.135 136 If constipation worsens or the desired effect is not achieved with acceptable adverse effects with the usual dosage of 1–6 doses per day, consider combined therapy or alternative treatment.135 136 166
Cautions for Colestid
Known hypersensitivity to colestipol or any ingredient in the formulation.166
To avoid accidental inhalation or esophageal distress, do not administer colestipol hydrochloride for oral suspension in its dry form.166 Always mix colestipol hydrochloride granules with water or other fluids before ingesting.166 (See Administration under Dosage and Administration.)
Individuals with phenylketonuria (i.e., homozygous genetic deficiency of phenylalanine hydroxylase) and other individuals who must restrict their intake of phenylalanine should be warned that Flavored Colestid granules for oral suspension contain aspartame (NutraSweet), which is metabolized in the GI tract following oral administration to provide 18.2 mg of phenylalanine per 7.5-g packet.166
Generally has no clinically relevant effect on serum triglyceride concentrations,100 167 but may increase triglyceride concentrations in some patients.167 Use with caution in patients with baseline triglyceride concentrations of 250–299 mg/dL; discontinue when triglyceride concentrations >400 mg/dL.350
Do not use in patients with baseline fasting triglyceride concentrations ≥300 mg/dL or in those with primary dysbetalipoproteinemia (Fredrickson type III).350
Mild and, occasionally, severe constipation has occurred.166 167 Exacerbation of preexisting constipation and aggravation of hemorrhoids secondary to constipation may occur.166 167 Encourage increased fluid and fiber intake to alleviate constipation;111 114 121 136 166 167 173 a stool softener can be added if necessary.135 136 166 167 In addition, adjust dosage carefully and titrate slowly to minimize adverse GI effects (e.g., fecal impaction).135 166 167 (See Dosage under Dosage and Administration.) Make particular effort to avoid constipation in patients with symptomatic CHD.166 167 Discontinuation of colestipol therapy may be required in some patients.166 167
Difficulty swallowing and transient esophageal obstruction have been reported rarely.166 167 Patients with a history of swallowing difficulties or choking with food, liquids, or other tablets or capsules should consult a clinician before initiating therapy with colestipol hydrochloride tablets.167 If abdominal pressure or discomfort (secondary to esophageal obstruction) occurs, advise patients to consult a clinician prior to administering the next dose.167
Abdominal discomfort (including pain and cramping), belching, flatulence, indigestion, heartburn, nausea, vomiting, and diarrhea or loose stools also have been reported.166 167 Bleeding hemorrhoids and blood in the stool have been reported infrequently.166 167 Peptic ulceration, cholecystitis, and cholelithiasis have been reported occasionally but are not necessarily drug-related.166 167
Fat-soluble Vitamin Deficiency
May interfere with the absorption of folic acid and fat-soluble vitamins (e.g., vitamins A, D, E, K).166 167 Prolonged use may be associated with an increased bleeding tendency as a result of hypoprothrombinemia secondary to vitamin K deficiency.166 167 (See Specific Drugs under Interactions.)
Common Adverse Effects
Interactions for Colestid
Effects on GI Absorption of Drugs
May bind to a number of drugs in the GI tract and may delay or reduce their absorption.166 167 Instruct patients to allow as long a time interval as possible between ingestion of other drugs and colestipol.166 167 The manufacturer recommends administering other drugs at least 1 hour before or 4 hours after colestipol.166 167
Consider the possibility that discontinuance of colestipol in patients stabilized on potentially toxic drugs that bind to the resin may lead to toxicity and that administration of colestipol to patients stabilized on other drugs may reduce the effect of these drugs.166 167
Antidiabetic agents (sulfonylureas)
Decreased antilipemic effects of colestipold
β-adrenergic blocking agents (propranolol)
Diuretics, thiazide (e.g., hydrochlorothiazide, chlorothiazide)
Fat-soluble Vitamins (i.e., vitamins A, D, E, K)
Consider supplemental administration of vitamins A and D if colestipol is to be given for a prolonged period.d
Phosphate supplements, oral
Granules for Suspension
Actions and Spectrum
Binds to bile acids in the intestine and forms a nonabsorbable complex that is excreted in feces.166 167 Partial removal of bile acids from the enterohepatic circulation via this mechanism results in increased conversion of cholesterol to bile acids in the liver.166 167 This causes an increased demand for cholesterol in liver cells, resulting in a compensatory increase in hepatic uptake (and thus systemic clearance) of circulating LDL-cholesterol.166 167
Advice to Patients
Inform patients that colestipol hydrochloride tablets may be larger than typical tablets or capsules.167 (See GI Effects under Cautions.)
For phenylketonurics, importance to inform them that Flavored Colestid granules for oral suspension contains aspartame.166
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
5 g/packet or calibrated scoop*
Colestipol Hydrochloride for Oral Suspension
5 g/7.5 g packet or calibrated scoop
Colestid Flavored Granules
AHFS DI Essentials. © Copyright 2018, Selected Revisions November 20, 2014. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
100. Pfizer. Colestid and Flavored Colestid (colestipol hydrochloride for oral suspension) prescribing information. New York, NY; 2006 Jun.
101. Anon. Addition to labeling of cholestyramine. FDA Drug Bull. 1985; 15:7-8. http://www.ncbi.nlm.nih.gov/pubmed/3858190?dopt=AbstractPlus
102. National Institutes of Health Offices of Medical Applications of Research. Consensus conference: lowering blood cholesterol to prevent heart disease. JAMA. 1985; 25:2080-6.
103. Rahimtoola SH. Cholesterol and coronary heart disease: a perspective. JAMA. 1985; 253:2094-5. http://www.ncbi.nlm.nih.gov/pubmed/3974101?dopt=AbstractPlus
104. American Heart Association Committee to Design a Dietary Treatment of Hyperlipoproteinemia. Recommendations for treatment of hyperlipidemia in adults: a joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation. 1984; 69:1065-90A. http://www.ncbi.nlm.nih.gov/pubmed/6713610?dopt=AbstractPlus
105. American Medical Association Council on Scientific Affairs. Dietary and pharmacologic therapy for the lipid risk factors. JAMA. 1983; 250:1873-9. http://www.ncbi.nlm.nih.gov/pubmed/6620484?dopt=AbstractPlus
106. Glueck CJ. Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. Am Heart J. 1985; 110:1107-15. http://www.ncbi.nlm.nih.gov/pubmed/2865887?dopt=AbstractPlus
107. National Heart, Lung and Blood Institute Lipid Metabolism-Atherogenesis Branch. The Lipid Research Clinics Coronary Primary Prevention Trial results. Part I: reduction in incidence of coronary heart disease. JAMA. 1984; 251:351-64. http://www.ncbi.nlm.nih.gov/pubmed/6361299?dopt=AbstractPlus
108. National Heart, Lung and Blood Institute Lipid Metabolism-Atherogenesis Branch. The Lipid Research Clinics Coronary Primary Prevention Trial results. Part II: relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251:365-74. http://www.ncbi.nlm.nih.gov/pubmed/6361300?dopt=AbstractPlus
109. Kronmal RA. Commentary on the published results of the lipid research clinics coronary primary prevention trial. JAMA. 1985; 253:2091-3. http://www.ncbi.nlm.nih.gov/pubmed/3883022?dopt=AbstractPlus
110. Oliver MF. Hypercholesterolaemia and coronary heart disease: an answer. BMJ. 1984; 288:423-4. http://www.ncbi.nlm.nih.gov/pubmed/6419948?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1444755&blobtype=pdf
111. Kane JP, Malloy MJ, Tun P et al. Normalization of low density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 1981; 304:251-8. http://www.ncbi.nlm.nih.gov/pubmed/7003391?dopt=AbstractPlus
112. Illingworth DR, Phillipson BE, Rapp JH et al. Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia. Lancet. 1981; 1:296-7. http://www.ncbi.nlm.nih.gov/pubmed/6109940?dopt=AbstractPlus
113. Kuo PT, Kostis JB, Moreyra AE et al. Familial type II hyperlipoproteinemia with coronary heart disease: effect of diet-colestipol-nicotinic acid treatment. Chest. 1981; 79:286-91. http://www.ncbi.nlm.nih.gov/pubmed/7471860?dopt=AbstractPlus
114. Glueck CJ. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Ann Intern Med. 1982; 96:475-82. http://www.ncbi.nlm.nih.gov/pubmed/7039445?dopt=AbstractPlus
115. Glueck CJ, Fallat RW, Tsang RG. Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin. Pediatrics. 1976; 57:68-74. http://www.ncbi.nlm.nih.gov/pubmed/174057?dopt=AbstractPlus
116. Schwarz KB, Goldstein PD, Witztum JL et al. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics. 1980; 65:243-50. http://www.ncbi.nlm.nih.gov/pubmed/7354970?dopt=AbstractPlus
117. Schlierf G, Mrozik K, Heuck CC et al. “Low-dose” colestipol in children, adolescents and young adults with familial hypercholesterolemia. Atherosclerosis. 1982; 41:133-8. http://www.ncbi.nlm.nih.gov/pubmed/7073790?dopt=AbstractPlus
118. Glueck CJ. Therapy of familial and acquired hyperlipoproteinemia in children and adolescents. Prev Med. 1983; 12:835-47. http://www.ncbi.nlm.nih.gov/pubmed/6676731?dopt=AbstractPlus
119. Tsang RC, Roginsky MS, Mellies MJ et al. Plasma 25-hydroxy-vitamin D in familial hypercholesterolemic children receiving colestipol resin. Pediatr Res. 1978; 12:980-2. http://www.ncbi.nlm.nih.gov/pubmed/724301?dopt=AbstractPlus
120. American Health Foundation. Summary and recommendations of the Conference on Blood Lipids in Children: optimal levels for early prevention of coronary artery disease. Prev Med. 1983; 12:728-40. http://www.ncbi.nlm.nih.gov/pubmed/6676727?dopt=AbstractPlus
121. Hoeg JM, Gregg RE, Brewer HB. An approach to the management of hyperlipoproteinemia. JAMA. 1986; 255:512-21. http://www.ncbi.nlm.nih.gov/pubmed/3510334?dopt=AbstractPlus
122. National Institutes of Health Office of Medical Applications of Research. Consensus conference: treatment of hypertriglyceridemia. JAMA. 1984; 251:1196-200. http://www.ncbi.nlm.nih.gov/pubmed/6582287?dopt=AbstractPlus
123. Forman MB, Baker SG, Mieny CJ et al. Treatment of homozygous familial hypercholesterolaemia with portacaval shunt. Atherosclerosis. 1982; 41:349-61. http://www.ncbi.nlm.nih.gov/pubmed/7066082?dopt=AbstractPlus
124. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975; 1:1208-11. http://www.ncbi.nlm.nih.gov/pubmed/48833?dopt=AbstractPlus
125. Postiglione A, Thompson GR. Experience with plasma-exchange in homozygous familial hypercholesterolaemia. Prog Clin Biol Res. 1985; 188:213-20. http://www.ncbi.nlm.nih.gov/pubmed/3903770?dopt=AbstractPlus
126. Starzl TE, Chase HP, Ahrens EH Jr et al. Portacaval shunt in patients with familial hypercholesterolemia. Ann Surg. 1983; 198:273-83. http://www.ncbi.nlm.nih.gov/pubmed/6615051?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1353292&blobtype=pdf
127. King MEE, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med. 1980; 302:1457-9. http://www.ncbi.nlm.nih.gov/pubmed/7374711?dopt=AbstractPlus
128. Hoeg JM, Demosky SJ Jr, Schaefer EJ et al. The effect of portacaval shunt on hepatic lipoprotein metabolism in familial hypercholesterolemia. J Surg Res. 1985; 39:369-77. http://www.ncbi.nlm.nih.gov/pubmed/4057999?dopt=AbstractPlus
129. Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. N Engl J Med. 1985; 312:1300-10. http://www.ncbi.nlm.nih.gov/pubmed/3887163?dopt=AbstractPlus
130. Bilheimer DW, Goldstein JL, Grundy SM et al. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med. 1984; 311:1658-64. http://www.ncbi.nlm.nih.gov/pubmed/6390206?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2975980&blobtype=pdf
131. Mancini M, Postiglione A, Farinaro E et al. Diet, drugs, and plasma exchange in the treatment of hyperlipidemia in childhood. Prev Med. 1983; 12:848-53. http://www.ncbi.nlm.nih.gov/pubmed/6676732?dopt=AbstractPlus
132. American Heart Association Committee on Atherosclerosis and Hypertension in Childhood of the Council of Cardiovascular Disease in the Young and the Nutrition Committee. Diagnosis and treatment of primary hyperlipidemia in childhood: a joint statement for physicians by the Committee on Atherosclerosis and Hypertension in Childhood of the Council of Cardiovascular Disease in the Young and the Nutrition Committee. Circulation. 1986: 74:1181-8A.
133. Hibbard DM, Peters JR, Hunninghake DB. Effect of cholestyramine and colestipol on the plasma concentrations of propranolol. Br J Clin Pharmacol. 1984; 18:337-42. http://www.ncbi.nlm.nih.gov/pubmed/6487473?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1463656&blobtype=pdf
134. Mangini RJ, ed. Drug interaction facts. St. Louis: JB Lippincott Co; 1985(Jan):110a.
135. The Upjohn Company. Colestid (colestipol hydrochloride) granules prescribing information. Kalamazoo, MI; 1990 Apr.
136. The Expert Panel (coordinated by the National Heart, Lung, and Blood Institute). Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988; 148:36-69. http://www.ncbi.nlm.nih.gov/pubmed/3422148?dopt=AbstractPlus
137. Bilheimer DW. Familial hypercholesterolemia: there is a need for early detection and treatment. JAMA. 1987; 257:69-70. http://www.ncbi.nlm.nih.gov/pubmed/3783906?dopt=AbstractPlus
138. Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA. 1987; 257:33-8. http://www.ncbi.nlm.nih.gov/pubmed/3537351?dopt=AbstractPlus
139. Witztum JL. Intensive drug therapy of hypercholesterolemia. Am Heart J. 1987; 113(2 Part 2):603-9. http://www.ncbi.nlm.nih.gov/pubmed/3544777?dopt=AbstractPlus
140. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of colestipol-niacin therapy on coronary atherosclerosis and coronary bypass grafts. JAMA. 1987; 257:3233-40. http://www.ncbi.nlm.nih.gov/pubmed/3295315?dopt=AbstractPlus
141. Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern Med. 1984; 101:598-604. http://www.ncbi.nlm.nih.gov/pubmed/6567462?dopt=AbstractPlus
142. Mabuchi H, Sakai T, Sakai Y et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia: additive effects of compactin and cholestyramine. N Engl J Med. 1983; 308:609-13. http://www.ncbi.nlm.nih.gov/pubmed/6828091?dopt=AbstractPlus
143. Malloy MJ, Kane JP, Kunitake ST et al. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med. 1987; 107:616-23. http://www.ncbi.nlm.nih.gov/pubmed/3662275?dopt=AbstractPlus
144. Tobert JA. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation. 1987; 76:534-8. http://www.ncbi.nlm.nih.gov/pubmed/3113763?dopt=AbstractPlus
145. Brown MS, Goldstein JL. The hyperlipoproteinemias and other disorders of lipid metabolism. In: Harrison’s principles of internal medicine. 11th ed. New York: McGraw-Hill Book Co; 1987;1650-61.
146. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem. 1977; 46:897-930. http://www.ncbi.nlm.nih.gov/pubmed/197883?dopt=AbstractPlus
147. Brown MS, Goldstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest. 1983; 72:743-7. http://www.ncbi.nlm.nih.gov/pubmed/6309907?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1129238&blobtype=pdf
148. Heber D, Koziol BJ, Henson LC. Low density lipoprotein receptor regulation and cellular basis of atherosclerosis: implications for nutritional and pharmacologic treatment of hypercholesterolemia. Am J Cardiol. 1987; 60(Suppl):4-8G.
149. Thompson GR, Ford J, Jenkinson M et al. Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia. Q J Med. 1986; 60:803-11. http://www.ncbi.nlm.nih.gov/pubmed/3640503?dopt=AbstractPlus
150. East C, Grundy SM, Bilheimer DW. Normal cholesterol levels with lovastatin (mevinolin) therapy in a child with homozygous familial hypercholesterolemia following liver transplantation. JAMA. 1986; 256:2843-8. http://www.ncbi.nlm.nih.gov/pubmed/3534334?dopt=AbstractPlus
151. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988; 319:24-33. http://www.ncbi.nlm.nih.gov/pubmed/3288867?dopt=AbstractPlus
152. Reviewers’ comments on lovastatin (personal observations); 1988 Jul.
153. McNamara DJ, Ahrens EH Jr, Kolb R et al. Treatment of familial hypercholesterolemia by portcaval anastomosis: effect on cholesterol metabolism and pool sizes. Proc Natl Acad Sci USA. 1983; 80:564-8. http://www.ncbi.nlm.nih.gov/pubmed/6572906?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=393420&blobtype=pdf
154. Witztum JL, Williams JC, Ostlund R et al. Successful plasmapheresis in a 4-year-old child with homozygous familial hypercholesterolemia. J Pediatr. 1980; 97:615-8. http://www.ncbi.nlm.nih.gov/pubmed/6775065?dopt=AbstractPlus
155. Graisely B, Cloarec M, Salmon S et al. Extracorporeal plasma therapy for homozygous familial hypercholesterolaemia. Lancet. 1980; 2:1147. http://www.ncbi.nlm.nih.gov/pubmed/6107765?dopt=AbstractPlus
156. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet. 1981; 2:1005-7. http://www.ncbi.nlm.nih.gov/pubmed/6118475?dopt=AbstractPlus
157. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. BMJ. 1985; 291:1671-3. http://www.ncbi.nlm.nih.gov/pubmed/3935235?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1418783&blobtype=pdf
158. Illingworth DR, Bacon SP, Larsen KK. Long-term experience with HMG-CoA reductase inhibitors in the therapy of hypercholesterolemia. Atheroscler Rev. 1988; 18:161-87.
159. American Heart Association. AHA conference report on cholesterol. Circulation. 1989; 80:715-48. http://www.ncbi.nlm.nih.gov/pubmed/2670320?dopt=AbstractPlus
160. Cashin-Hemphill L, Mack WJ, Pogoda JM et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990; 264:3013-7. http://www.ncbi.nlm.nih.gov/pubmed/2243429?dopt=AbstractPlus
161. Working Group on Management of Patients with Hypertension and High Blood Cholesterol. National education programs working group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med. 1991; 114:224-37. http://www.ncbi.nlm.nih.gov/pubmed/1984747?dopt=AbstractPlus
162. The Upjohn Company. Colestid (colestipol hydrochloride) granules prescribing information. In: Barnhart ER, publisher. Physicians’ desk reference. 45th ed. Oradell, NJ: Medical Economics Company Inc; 1991(Suppl A):A72.
163. The Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992; 89(Suppl):525-84. http://www.ncbi.nlm.nih.gov/pubmed/1538956?dopt=AbstractPlus
164. American Academy of Pediatrics Committee on Nutrition. Statement on cholesterol. Pediatrics. 1992; 90:469-73. http://www.ncbi.nlm.nih.gov/pubmed/1518712?dopt=AbstractPlus
165. The Expert Panel. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994; 89:1329-1445.
166. Upjohn. Colestid (colestipol hydrochloride for oral suspension) and Flavored Colestid (colestipol hydrochloride for oral suspension) granules for oral suspension prescribing information. Kalamazoo, MI; 1998 Mar.
167. Pfizer. Colestid (micronized colestipol hydrochloride) tablets prescribing information. New York, NY; 2006 Jun.
168. Gibbons RJ, Chatterjee K, Daley J et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 1999; 33:2092-197. http://www.ncbi.nlm.nih.gov/pubmed/10362225?dopt=AbstractPlus
169. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet. 1994; 344:1383-9. http://www.ncbi.nlm.nih.gov/pubmed/7968073?dopt=AbstractPlus
170. Sacks FN, Pfeffer MA, Maye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9. http://www.ncbi.nlm.nih.gov/pubmed/8801446?dopt=AbstractPlus
171. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57. http://www.ncbi.nlm.nih.gov/pubmed/9841303?dopt=AbstractPlus
172. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97. http://www.ncbi.nlm.nih.gov/pubmed/11368702?dopt=AbstractPlus
173. Anon. Choice of lipid-regulating drugs. Med Lett Drugs Ther. 2001; 43:43-8. http://www.ncbi.nlm.nih.gov/pubmed/11378632?dopt=AbstractPlus
174. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Adult Treatment Panel III Report. From AHA web site. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm
350. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; :. http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a
352. Eckel RH, Jakicic JM, Ard JD et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63:2960-84. http://www.ncbi.nlm.nih.gov/pubmed/24239922?dopt=AbstractPlus
357. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128 Suppl 5:S213-56. http://www.ncbi.nlm.nih.gov/pubmed/22084329?dopt=AbstractPlus
c. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. Baltimore, MD: Williams & Wilkins; 2002:324-5.
d. AHFS Drug Information 2003. McEvoy GK , ed. Colestipol hydrochloride. Bethesda, MD: American Society of Health-System Pharmacists; 2003:1594-6.
More about Colestid (colestipol)
- Colestid Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews
- Generic Availability
- Drug class: bile acid sequestrants